Mannkind (MNKD) Operating Income Growth (5y) (2015 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Mannkind | 1.09 Bn | 956.66 Mn | 82.66 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 23.08% |
| Dec 31, 2025 | 20.20% |
| Sep 30, 2025 | 32.41% |
| Jun 30, 2025 | 21.70% |
| Mar 31, 2025 | 38.69% |
| Dec 31, 2024 | 34.08% |
| Sep 30, 2024 | 28.13% |
| Jun 30, 2024 | 28.60% |
| Mar 31, 2024 | 26.48% |
| Dec 31, 2023 | 24.71% |
| Sep 30, 2023 | 17.47% |
| Jun 30, 2023 | 15.82% |
| Mar 31, 2023 | 25.87% |
| Dec 31, 2022 | 15.01% |
| Sep 30, 2022 | 19.36% |
| Jun 30, 2022 | 8.32% |
| Mar 31, 2022 | -1.63% |
| Dec 31, 2021 | -15.16% |
| Sep 30, 2021 | -15.50% |
| Jun 30, 2021 | 11.69% |
| Mar 31, 2021 | 20.92% |
| Dec 31, 2020 | 38.63% |
| Sep 30, 2020 | 18.89% |
| Jun 30, 2020 | 19.93% |
| Mar 31, 2020 | 20.00% |
| Dec 31, 2019 | 17.72% |
| Sep 30, 2019 | 25.51% |
| Jun 30, 2019 | 30.96% |
| Mar 31, 2019 | 20.07% |
| Dec 31, 2018 | 30.19% |
| Sep 30, 2018 | 13.61% |
| Jun 30, 2018 | 13.16% |
| Mar 31, 2018 | 5.97% |
| Dec 31, 2017 | 2.95% |
| Sep 30, 2017 | 4.51% |
| Jun 30, 2017 | 6.45% |
| Mar 31, 2017 | 10.39% |
| Dec 31, 2016 | 17.29% |
| Sep 30, 2016 | 41.17% |
| Jun 30, 2016 | 13.37% |
| Mar 31, 2016 | 12.04% |
| Dec 31, 2015 | -53.43% |
| Sep 30, 2015 | 9.38% |
| Jun 30, 2015 | 8.38% |